A team of fusion researchers at TAE Technologies, Inc., in the U.S., working with colleagues from the University of ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...

and anti-RSV F protein/gold antibodies, colorized yellow, shedding from the surface of human lung cells. (National Institute of Allergy and Infectious Diseases, NIH via AP, File) (Uncredited, National ...

Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's efficacy in hospitalized infants ≤6 months, and demonstrating long-term ...

Leveraging structural biology-based design, we engineered the RSV pre-F protein and validated the potential of IIC self-splicing introns as a vaccine platform for preventing infectious diseases.

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.

Constitutively-activated chimeric TRK fusion proteins can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines. 1 In the U.S., VITRAKVI is approved for the ...